SCRN3 Antibody

Product Specifications

Background

SCRN3 Antibody: SCRN3 is a member of the secernin family of proteins which includes the homologous SCRN1, a protein that was first identified as being involved in the regulation of exocytosis from peritoneal mast cells. Little is known of SCRN3, but studies have shown that SCRN1 may possess epitopes that function as tumor-associated antigens in gastric cancers and increased SCRN1 expression in patients with colorectal cancer correlated with poor prognosis, suggesting that SCRN3 may also be involved in protein secretion or the regulation of cell growth.

NCBI Gene ID

79634

Swiss Prot

Q0VDG4

Accession Number

AAI19685

Host

Rabbit

Reactivity

Human, Mouse

Clonality

Polyclonal

Conjugation

Unconjugated

Type

Primary Antibodies

Field of Research

Cancer, Cell Cycle

Purification

SCRN3 Antibody is affinity chromatography purified via peptide column.

Positive Control

Cat. No. 1311 - Human Breast Tissue Lysate

Concentration

1 mg/mL

Homology

Predicted species reactivity based on immunogen sequence: Bovine: (100%)

Buffer

SCRN3 Antibody is supplied in PBS containing 0.02% sodium azide.

Modification

None

Shipping Conditions

Blue Ice

Storage Conditions

SCRN3 antibody can be stored at 4˚ C for three months and -20˚ C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Fragment

IgG

Symbol

SCRN3

Positive Control 2

Cat. No. 17-010 - HEK293 Cell Slide

NCBI Official Name

Secernin 3

NCBI Organism

Homo sapiens

Background Reference 01

Way G, Morrice N, Smythe C, et al. Purification and identification of Secernin, a novel cytosolic protein that regulates exocytosis in mast cells. Mol. Biol. Cell2002; 13:3344-54.

Background Reference 02

Suda T, Tsunoda T, Uchida N, et al. Identification of secernin 1 as a novel immunotherapy target for gastric cancer using the expression profiles of cDNA microarray. Cancer Sci.2006; 97:411-9.